Form 8-K/A

8-K/A — Wellgistics Health, Inc.

Accession: 0001493152-26-018326

Filed: 2026-04-21

Period: 2026-04-17

CIK: 0002030763

SIC: 5122 (WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES)

Item: Entry into a Material Definitive Agreement

Item: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item: Unregistered Sales of Equity Securities

Item: Regulation FD Disclosure

Item: Financial Statements and Exhibits

Documents

8-K/A — form8-ka.htm (Primary)

EX-10.1 (ex10-1.htm)

EX-99.1 (ex99-1.htm)

GRAPHIC (ex99-1_001.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K/A

8-K/A (Primary)

Filename: form8-ka.htm · Sequence: 1

true

0002030763

2026-04-17

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K/A

(Amendment No. 1)

CURRENT

REPORT

PURSUANT

TO SECTION 13 OR 15(d) OF THE

SECURITIES

EXCHANGE ACT OF 1934

Date

of Report (Date of earliest event reported): April 17, 2026

WELLGISTICS

HEALTH, INC.

(Exact

name of registrant as specified in its charter)

Delaware

001-42530

93-3264234

(State

or other jurisdiction

incorporation)

(Commission

File

Number)

(IRS

Employer

Identification

No.)

3000

Bayport Drive

Suite

950

Tampa,

FL 33607

(Address

of principal executive offices, including zip code)

Registrant’s

telephone number, including area code: (844) 203-6092

Not

Applicable

(Former

name or former address, if changed since last report)

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written communications pursuant to Rule 425 under the

Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the

Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b)

under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c)

under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title of

each class

Trading Symbol(s)

Name of each

exchange on which registered

Common Stock, $0.0001 par

value per share

WGRX

The Nasdaq Capital Market

LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☒

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

EXPLANATORY

NOTE

This

Amendment No. 1 to the Current Report on Form 8-K filed on April 17, 2026 is being filed to include disclosure required under Item 3.01

that was inadvertently omitted.

Item

1.01 Entry into a Material Definitive Agreement.

April 13, 2026, Wellgistics Health, Inc. (the “Company”) entered into a Collaboration Agreement (the “Collaboration

Agreement”) with Kare Rx Hub, LLC (“Kare Hub”), Kare Pharmtech, LLC (“Kare Pharmtech”), and Healthstar

Technologies, LLC (“Healthstar”), pursuant to which the parties agreed to collaborate through a newly formed limited liability

company structure.

The

Collaboration Agreement provides for the creation of a separate limited liability company, Healthstar, in which the Company will hold

a 51% membership interest and Kare Hub will hold a 49% membership interest. Pursuant to the Collaboration Agreement, at the closing of

the transactions contemplated thereby (the “Closing”), Kare Hub will assign, transfer, convey and deliver to Healthstar certain

intellectual property and related assets and records as described in the Collaboration Agreement (the “Transferred Assets”),

subject to Kare Hub’s security and collateral rights as provided in the Collaboration Agreement.

consideration for the Transferred Assets, the Collaboration Agreement provides that the Company will pay Kare Pharmtech an aggregate

purchase price of $2,000,000, payable in unregistered shares of the Company’s common stock (the “Purchase Shares”),

delivered in installments. The Collaboration Agreement provides that (i) 1,500,000 Purchase Shares will be delivered to Kare Pharmtech

at Closing and (ii) thereafter, on or prior to April 1, 2027 (the “Reconciliation Date”), the Company may, at its sole option

and election, deliver additional Purchase Shares such that the aggregate value of all Purchase Shares delivered to Kare Pharmtech equals

$2,000,000, with the number of additional Purchase Shares to be determined using a two-day volume-weighted average price of the Company’s

common stock prior to the date of issuance of such additional shares.

The

Collaboration Agreement further provides, among other things, that: (a) the Purchase Shares are intended to be “restricted securities”

and will bear a restrictive legend and be subject to applicable transfer restrictions; (b) Kare Pharmtech agreed to a 12-month lock-up

period from the applicable payment date, subject to certain exceptions (including with the Company’s prior written consent); (c)

the Closing is to occur remotely by exchange of documents and signatures at 10:00 a.m. Eastern Time on or about April 10, 2026, or at

such other time and place (or in such other manner) as the parties may mutually agree in writing, and is subject to satisfactory completion

of due diligence (including IT and financial due diligence), with either party having the right to terminate the Collaboration Agreement

in its entirety if dissatisfied upon completion of such due diligence; (d) the parties generally do not assume one another’s liabilities

and obligations, and liabilities and obligations remain with the applicable party as described in the Collaboration Agreement; and (e)

at Closing, the parties will deliver customary closing documentation, including an operating agreement for Healthstar, an assignment

and assumption agreement, and certain security documentation (including a UCC financing statement and an intellectual property security

agreement) in favor of Kare Hub.

The

foregoing description of the Collaboration Agreement does not purport to be complete and is qualified in its entirety by reference to

the full text of the Collaboration Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated

herein by reference.

Item

3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

April 13, 2026, Wellgistics Health, Inc. (the “Company”) received a written notification (the “Notification Letter”)

from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in

compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on the Nasdaq Capital Market to maintain a minimum of

$2,500,000 in stockholders’ equity for continued listing.

reported in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, the Company’s stockholders’

equity was $(12,447,801). Nasdaq further noted that, as of April 13, 2026, the Company does not meet the alternative continued listing

standards under the Nasdaq Capital Market requirements, specifically the market value of listed securities standard of $35 million or

the net income from continuing operations standard of $500,000 in the most recently completed fiscal year or in two of the last three

most recently completed fiscal years.

The

Notification Letter does not result in the immediate delisting of the Company’s securities from the Nasdaq Capital Market. In accordance

with Nasdaq’s listing rules, the Company has been afforded 45 calendar days from the date of the Notification Letter, or until

May 28, 2026, to submit a plan to regain compliance with the stockholders’ equity requirement. If Nasdaq accepts the Company’s

plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the date of the Notification Letter to evidence compliance.

In considering whether to accept the Company’s plan, Nasdaq will consider such factors as the likelihood that the plan will result

in compliance with Nasdaq’s continued listing criteria, the Company’s past compliance history, the reasons for the Company’s

current non-compliance, other corporate events that may occur within the review period, the Company’s overall financial condition,

and its public disclosures. If the Company’s plan is not accepted, the Company will have the opportunity to appeal that decision

to a Nasdaq Hearings Panel pursuant to Listing Rule 5815(a).

The

Company intends to submit a compliance plan to Nasdaq within the prescribed period and is currently evaluating available options to regain

compliance with Listing Rule 5550(b)(1). There can be no assurance that the Company will be able to regain compliance with Nasdaq’s

continued listing requirements, that Nasdaq will accept the Company’s compliance plan, or that the Company will be able to maintain

its listing on the Nasdaq Capital Market.

Cautionary

Note Regarding Forward-Looking Statements

This

Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,

and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, but are not limited to,

statements regarding the Company’s plans to regain compliance with the Nasdaq continued listing requirements, the Company’s

ability to submit an acceptable compliance plan, and the Company’s ability to maintain its listing on the Nasdaq Capital Market.

These statements are based on management’s current expectations and involve risks and uncertainties that could cause actual results

to differ materially from those expressed or implied. Factors that could cause actual results to differ include, but are not limited

to, the Company’s ability to raise additional capital or otherwise improve its stockholders’ equity, general economic and

market conditions, and other risks and uncertainties set forth in the Company’s filings with the Securities and Exchange Commission,

including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The Company undertakes no obligation to update

or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by

law.

Item

3.02 Unregistered Sales of Equity Securities.

described under Item 1.01 above, pursuant to the Collaboration Agreement, the Company agreed to issue to Kare Pharmtech up to $2,000,000

of the Company’s common stock in connection with the transactions contemplated by the Collaboration Agreement, including the issuance

of 1,500,000 shares at Closing and, at the Company’s election, additional shares on or prior to the Reconciliation Date, subject

to the terms and conditions described in the Collaboration Agreement.

Any

issuance of Purchase Shares pursuant to the Collaboration Agreement is expected to be made in reliance on an exemption from the registration

requirements of the Securities Act of 1933, as amended, in a transaction not involving a public offering.

The

disclosure set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02.

Item

7.01 Regulation FD Disclosure.

April 14, 2026, the Company issued a press release announcing the execution of a definitive joint venture agreement with Kare Pharmtech’s

wholly owned subsidiary, Kare Rx Hub, LLC, and related matters. A copy of the press release is furnished as Exhibit 99.1 to this Current

Report on Form 8-K.

The

information in this Item 7.01 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of

Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities

of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the

Exchange Act, except as expressly set forth by specific reference in such filing.

Item

9.01. Financial Statements and Exhibits.

(d)

Exhibits.

The

following exhibits are filed as part of, or incorporated by reference into, this Report.

Exhibit No.

Description

10.1

Collaboration Agreement, dated effective April 13, 2026, by and among Wellgistics Health, Inc., Kare Rx Hub, LLC, Kare Pharmtech, LLC, and Healthstar Technologies, LLC.

99.1

Press release, dated April 14, 2026.

104*

Cover Page Interactive

Data File (formatted as Inline XBRL)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

Date: April 21, 2026

WELLGISTICS HEALTH, INC.

By:

/s/ Prashant Patel

Prashant Patel, President

EX-10.1

Filename: ex10-1.htm · Sequence: 2

Exhibit

10.1

COLLABORATION

AGREEMENT

This

Collaboration Agreement (this “Agreement”), dated Effective April 13, 2026, is entered into between Kare Rx Hub,

LLC, a Florida limited liability company (“Kare Hub”) its parent Kare Pharmtech, LLC, a Florida limited

liability company, (“Kare Pharmtech”), Wellgistics Health, Inc., a Delaware Company, (“Wellgistics”).

RECITALS

WHEREAS,

as part of the Collaboration, the Parties, will create a separate limited liability company wherein Wellgistics will be a 51% member

and Kare Rx Hub will hold 49% of the interests of Healthstar Technologies, LLC (“Healthstar Technologies”); AND

WHEREAS,

the Parties hereto have, after several consultations with each other, shown the intention to co-operate with each other and enter into

collaboration with each other.

NOW

THEREFORE, in consideration of the mutual promises and agreements set forth herein and other good and valuable consideration, the receipt

and sufficiency of which are hereby acknowledge, Kare Hub, Kare Pharmtech, and Wellgistics hereby agree as follows

Article

1 Contribution from Kare Hub.

1.1

Contribution of Assets from Kare Hub. Subject to the terms and conditions set forth herein, at the Closing, Kare Hub shall assign,

transfer, convey and deliver to Healthstar Technologies, LLC the Transfer IP, defined below, which shall be subject to Kare Hub’s

security and collateral rights as outlined herein (collectively the “Transferred Asset”). Wellgistics shall pay to Kare Pharmtech

the Purchase Price outlined in Section 3 hereof. The Transferred Asset shall be free and clear of any and all Encumbrances, subject to

the security interest and collateral rights of Kare Hub as outlined in this agreement and any financing statements used to secure the

Transferred Asset.

1.2

For the purposes of this agreement the Transfer IP shall mean all national, international and foreign (to the United States) patents

and applications therefor owned by Kare Hub on the date of this Agreement that pertain to the Purchased Assets, including, without limitation,

the Transfer IP; (ii) all, rights in respect of (including, without limitation, the right to take enforcement action and claim damages),:

inventions (whether or not patentable), invention disclosures, improvements, trade secrets, proprietary information, know-how, technology,

data, tangible or intangible confidential and/or proprietary information, rights of confidentiality (including the benefit of duties

of confidentiality and covenants given to the Kare Hub by third-parties), and all documentation relating to any of the foregoing, in

each case to the extent owned by Kare Hub on the date of this Agreement and pertaining to any or all of the Purchased Assets; (iii) all

copyrights, trademarks, copyright registrations and applications therefor, and trademark registrations and applications therefor, owned

by Kare Hub on the date of this Agreement, and all other rights corresponding to any of the items in the foregoing clauses (i)-(iii)

throughout the world, in each case to the extent owned by Kare Hub and pertaining to the Purchased Assets; and (iv) all goodwill of Kare

Hub that is associated with the Purchased Assets (all the foregoing being “Transfer IP”). In addition, all data, files,

documents and records (in whatever media, including electronically stored information) owned or held by Kare Hub on the date of this

Agreement with respect to, or pertaining or related to, the Purchased Assets (as defined below), including, without limitation, all laboratory

notebooks, patent prosecution records, materials or correspondence, regulatory filings (together with all draft filings and all data

and other information collated or held in connection with any anticipated regulatory filing), records or correspondence, regulatory approvals,

manufacturing records, reports or correspondence, and pre-clinical and clinical study results and reports (including any the foregoing

held by others on behalf of Kare Hub) (all the foregoing being the “Records”). Kare Hub may retain copies of such

Records if and to the extent required to comply with applicable law and shall use any such retained copies of Records for no other purpose

and such copies of Records shall be safely and securely held by the Kare Hub so as to prevent unauthorized access thereto;

Collaboration Agreement Page 1 of 9

Article

2 Non-Assumption of Liabilities

2.1

Non-Assumption of Liabilities; Excluded Liabilities. Notwithstanding any provision in this Agreement or any other writing to the

contrary, and to clarify neither party is assuming any liability or obligation of either Party or any other affiliate of either Party

(or any predecessor owner of all or part of the Transferred Assets) of whatever nature, whether presently in existence, incurred or a

result of the transactions contemplated by this Agreement (the “Contemplated Transactions”), or arising or asserted

hereafter. All liabilities and obligations of either Party or any other affiliate of either Party (or any predecessor owner of all or

part of the Transferred Asset) of whatever nature, whether presently in existence, incurred or a result of the Contemplated Transactions,

or arising or asserted hereafter, remain the liabilities and obligations of each individual Party (all such liabilities and obligations

shall be referred to as the “Excluded Liabilities”).

Article

3 Contribution Purchase Price.

3.1

Purchase Price and Reconciliation. The Purchase Price shall be set at Two Million ($2,000,000) dollars which shall be payable

in unregistered common shares of Wellgistics Health Inc. (the “Purchase Shares”) payable in installments as follows:

(i) One Million Five Hundred Thousand (1,500,000) Purchase Shares shall be delivered to Kare Pharmtech at Closing; thereafter, (ii) Wellgistics

shall have the right, at its sole option and election, to reconcile the balance and deliver the additional amount of Purchase Shares

at any time it may choose on or prior to April 1, 2027 (the “Reconciliation Date”), such that the aggregate amount of all

Purchased Shares delivered to Kare Pharmtech equals a total value of $2,000,000 in United States Dollars. The number of additional Purchase

Shares deliverable upon reconciliation shall be calculated using a 2-day VWAP of Wellgistics common shares prior to the date of issuance

of such additional shares.

3.2

Purchase Shares. The Purchase Shares issued to Kare Pharmtech as part of this Agreement shall be “restricted securities”

as defined in Rule 144 under the Securities Act of 1933, as amended, and shall be subject to all applicable restrictions on transfer

under federal and state securities laws, including Rule 144. Kare Pharmtech acknowledges that the Purchase Shares will bear a restrictive

legend to such effect and may not be sold, transferred, or otherwise disposed of except in compliance with applicable securities laws.

Kare Pharmtech further agrees to a lock-up period of twelve (12) months from the Payment Date during which Kare Pharmtech shall not sell,

transfer, pledge, hypothecate, or otherwise dispose of any Purchase Shares received on the Payment Date, except with Wellgistics’s

prior written consent.

Collaboration Agreement Page 2 of 9

Article

4 Closing

4.1

Time and Place. Subject to the terms and conditions of this Agreement, the consummation of the Contemplated Transactions (the “Closing”)

shall take place remotely by exchange of documents and signatures (or their electronic counterparts), at 10:00 a.m., Eastern Time, on

or about April 10, 2026, or at such other time or place or in such other manner as Kare Hub, Kare Pharmtech and Wellgistics may mutually

agree upon in writing. The date on which the Closing is to occur is herein referred to as the “Closing Date.” Notwithstanding

any other provisions set forth in this Agreement, the Closing shall be subject to the satisfactory completion of due diligence with respect

to each Party, including, without limitation, IT due diligence, and financial due diligence. If, either Party is dissatisfied upon completion

of such due diligence, either Party shall have the right, in its sole discretion, to elect to not proceed to Closing and to terminate

this Agreement in its entirety.

4.2

Actions at the Closing. At the Closing:

(a)

At the Closing, Kare Hub shall duly execute and deliver to Healthstar Technologies instruments of assignment or transfer with respect

to the Purchased Assets as Wellgistics may reasonably request and as may be necessary to vest in Healthstar Technologies good record

(where applicable) and marketable title to all of the Purchased Assets, in each case free and clear of all Encumbrances (together with

this Agreement, the “Ancillary Documents”).

(b)

At the Closing, the Records shall be delivered to Healthstar Technologies in such form and media as enables Healthstar Technologies ready

access thereto so as to permit Healthstar Technologies to Exploit such Records in substantially the same manner as Kare Hub has Exploited

the same (including, without limitation, the provision of any password required to access, or other means of decrypting, such Records).

Where Records are held in electronic format such Records shall be transferred to Healthstar Technologies by such means as Healthstar

Technologies may reasonably require so as to enable the same to be accessed through Healthstar Technologies’s computer systems.

(c)

Closing Deliverables.

(i)

the Closing, Kare Hub shall deliver to Wellgistics or Healthstar Technologies as the case may be:

A countersigned

Operating Agreement;

an assignment and assumption

agreement in the form agreeable between Healthstar Technologies and Kare Hub (the “Assignment and Assumption Agreement”)

and duly executed by Kare Hub, effecting the assignment to and assumption to Healthstar Technologies of the Purchased Assets including

the right, title and interest in and to any intellectual property rights;

Collaboration Agreement Page 3 of 9

a properly

completed and duly executed IRS Form W-9 with respect to Kare Hub; and

such other customary instruments

of transfer, assumption, filings or documents, in form and substance reasonably satisfactory to Healthstar Technologies, as may be

required to give effect to this Agreement.

(ii)

At the Closing,

Wellgistics along with Healthstar Technologies, as the case may be, shall deliver, or shall cause to be delivered, to Kare Hub or

Kare Pharmtech as the case may be:

UCC Financing

Statement executed by Healthstar Technologies in favor of Kare Hub;

Intellectual Property Security

Agreement executed by Healthstar Technologies in favor of Kare Hub;

Wellgistics shall deliver

to Kare Pharmtech by acceptable means of transferring the applicable Purchase Shares to the account designated by Kare Pharmtech

or as otherwise agreed among the parties, One Million Five hundred Thousand (1,500,000) Purchase Shares.

the Assignment and Assumption

Agreement duly executed by Healthstar Technologies;

A countersigned Operating

Agreement of Healthstar Technologies executed by Wellgistics; and

such other customary instruments

of transfer, assumption, filings or documents, in form and substance reasonably satisfactory to Kare Hub and/or Kare Pharmtech, as

may be required to give effect to this Agreement.

(iii)

Post Closing

Reconciliation. At any time on or prior to the Reconciliation Date, at Wellgistics’s sole option and election, Wellgistics

shall deliver to Kare Pharmtech, by acceptable means of transferring the applicable remaining amount of Purchase Shares to the account

designated by Kare Pharmtech or as otherwise agreed among the parties, such number of additional Purchase Shares as shall cause the

aggregate amount of all Purchased Shares delivered to Kare Pharmtech to equal a total share value of $2,000,000 in United States

Dollars, calculated using a 2-day VWAP of Wellgistics common shares prior to the date of issuance of such additional shares.

Collaboration Agreement Page 4 of 9

Article

5 Miscellaneous

5.1

Other Agreements Superseded; Waiver and Modification, Etc. This Agreement and all other instruments of transfer and other agreements

and arrangements to be entered into pursuant to this Agreement (all the foregoing being the “Transaction Documents”)

supersede all prior agreements or understandings, written or oral, between Kare Hub, on the one hand, and Wellgistics, on the other hand,

relating to the transaction, and the Transaction Documents shall incorporate the entire understanding of the Parties with respect thereto.

This Agreement may be amended or supplemented only by a written instrument signed by the each Party hereto. No waiver by any party of

any of the provisions hereof shall be effective unless explicitly set forth in writing and signed by the party so waiving. No failure

to exercise, or delay in exercising, any right or remedy arising from this Agreement shall operate or be construed as a waiver thereof.

No single or partial exercise of any right or remedy hereunder shall preclude any other or further exercise thereof or the exercise of

any other right or remedy.

5.2

Further Assurances. Kare Hub agrees, at any time at or after the Closing, at its own expense, to execute, acknowledge and deliver

any further deeds, assignments, conveyances and other assurances, documents and instruments of transfer reasonably requested by Wellgistics,

and to take any other action consistent with the terms of this Agreement that may reasonably be requested by Wellgistics, for the purpose

of assigning, transferring, granting, conveying and confirming to Wellgistics, or reducing to Wellgistics’s possession, any or

all of the Purchased Assets as well as any assets later identified by either Kare Hub or Wellgistics to be related to the Purchased Assets

that would have been, but for their later identification, assigned to Wellgistics at the Closing in order to give effect to the Parties’

intentions herein.

5.3

Notices. Notices and other communications hereunder (“Notices”) to any Party shall be delivered to such Party’s

address as set forth below (or to such other address for such Party as shall be specified by like notice made pursuant to this Section

9.3):

to Kare Hub or Kare PharmTech:

KARE

PharmTech, LLC

Attn:

Mital Panara

5600

Mariner St., Suite 220

Tampa,

FL 33609

E-mail:

to Wellgistics or Healthstar Technologies to:

Wellgistics

Health, Inc.

Attn:

Prashant Patel

3000

Bayport Drive, Suite 950

Tampa,

E-mail:

Collaboration Agreement Page 5 of 9

5.4

Law Governing. All matters arising out of or relating to this Agreement shall be governed by and construed in accordance with the

internal laws of the State of Florida, without giving effect to any choice or conflict of law provision or rule (whether of the State

of Florida or any other jurisdiction). Any legal action or proceeding arising out of or relating to this Agreement shall be brought exclusively

in the state or federal courts located in Tampa, Florida, and each party irrevocably submits to the exclusive jurisdiction of such courts

in any such action or proceeding and waives any objection it may now or hereafter have to venue or to convenience of forum. Each party

hereby irrevocably waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in any legal proceeding

directly or indirectly arising out of or relating to this Agreement or the transactions contemplated hereby.

5.5

No Third Party Beneficiaries. This Agreement shall not confer any rights or remedies upon any person other than the Parties and their

respective successors and permitted assigns.

5.6

Successors; Assignability. This Agreement shall inure to the benefit of and be binding upon the heirs, executors, administrators,

successors and permitted assigns of the Parties hereto. Kare Hub may not assign its rights or obligations hereunder without the prior

written consent of Wellgistics. Wellgistics may assign its rights and obligations hereunder to any Affiliate or in connection with a

merger, consolidation, or sale of all or substantially all of its assets without the prior consent of Kare Hub. Any assignment by Kare

Hub of this Agreement or Kare Hub’s rights or obligations under this Agreement shall not operate to release or relieve Kare Hub

from any of Kare Hub’s obligations under this Agreement. Any permitted assignment by Wellgistics shall release Wellgistics from

its obligations to the extent assumed by the assignee.

5.7

Counterparts. This Agreement may be executed in any number of counterparts and each such executed counterpart shall be deemed to

be an original instrument, but all such executed counterparts together shall constitute one and the same instrument. One Party may execute

one or more counterparts other than that or those executed by another Party, without thereby affecting the effectiveness of any such

signatures. Delivery of an executed counterpart of a signature page to this Agreement by electronic transmission (including PDF or facsimile)

shall be as effective as delivery of a manually executed counterpart of this Agreement.

5.8

Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors and

permitted assigns.

5.9

Expenses. All costs and expenses incurred in connection with this Agreement and the transactions contemplated hereby shall be paid

by the party incurring such costs and expenses; provided, however, that Kare Hub shall be responsible for all costs and expenses related

to curing any breaches of Kare Hub’s representations, warranties, or covenants, and any costs associated with obtaining third-party

consents required for the transaction.

Collaboration Agreement Page 6 of 9

5.10

Defined Terms Used in this Agreement. The following terms used in this Agreement shall be construed to have the meanings set forth

or referenced below.

“Action”

means any claim, action, causes of action, demand, lawsuit, arbitration, inquiry, audit, notice of violation, proceeding, litigation,

citation, summons, subpoena, or investigation of any nature, whether at law or in equity.

“Affiliate”

means, with respect to a Person, any other Person that directly or indirectly, through one or more intermediaries, controls, is controlled

by, or is under common control with, such Person. For purposes of this definition, “control” means the possession, directly

or indirectly, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership

of voting securities, by contract, or otherwise, and the terms “controlled by” and “under common control with”

have meanings correlative to the foregoing.

“Breach”

means: (a) with respect to a Contract, any one or more of the following (i) any inaccuracy in, or breach of, any representation or warranty

given in connection with such Contract (without giving effect to any materiality, material adverse effect, or similar qualifiers contained

therein), (ii) any default under, breach of, or failure to perform or comply with any covenant, agreement obligation, or undertaking

in connection with such Contract, (iii) any other contravention of such Contract, or (iv) the occurrence of (or event which with the

passage of time or the giving of notice, or both, would constitute) any default or event of default, however defined, under such Contract;

or (b) with respect to any Law or Order, any default, breach, or violation of, other contravention of or other failure to comply with,

such Law or Order or any obligation or restriction contained in or imposed by such Law or Order.

“Code”

means the Internal Revenue Code of 1986, as amended.

“Contract”

means any contract, lease, deed, mortgage, license, instrument, note, indenture, joint venture, or any other agreement, commitment, or

legally binding arrangement, whether written or oral.

“Encumbrance”

means any lien (statutory or otherwise), security interest, pledge, hypothecation, mortgage, encumbrance, assessment, lease, claim, levy,

license, defect in title, charge, or any other third party right, license or property interest of any kind, or any conditional sale or

other title retention agreement, right of first option, right of first refusal or similar restriction, any covenant not to sue, or any

restriction on use, transfer, receipt of income or exercise of any other attribute of ownership or any agreement to give any of the foregoing

in the future or similar encumbrance of any kind or nature whatsoever.

“Exploit”

means to make, have made, import, use, sell, offer for sale, and otherwise dispose of, including to develop, register, modify, enhance,

improve, manufacture, have manufactured, store, formulate, optimize, export, transport, distribute, commercialize, promote, market, have

sold and otherwise dispose of or otherwise exploit. “Exploitation” shall be construed accordingly.

Collaboration Agreement Page 7 of 9

“Governmental

Authority” means any federal, state, local or foreign government or political subdivision thereof, or any agency or instrumentality

of such government or political subdivision, or any self-regulated organization or other non-governmental regulatory authority or quasi-governmental

authority (to the extent that the rules, regulations or orders of such organization or authority have the force of Law), or any arbitrator,

court or tribunal of competent jurisdiction.

“Intellectual

Property” or “IP” means all patents (including any patent disclosures and all related continuation, continuation

in part, divisional, reissue, reexamination, utility model, renewals, extensions, certificate of invention and design patents), patent

applications and registrations(including any applications for registration), registered and unregistered trademarks, trademark applications,

registered and unregistered service marks, service mark applications, tradenames, copyrights, software and computer algorithms, inventions,

know-how, trade secrets, confidential information, database rights and rights in data, domain names, mask works, information and proprietary

rights and processes, similar or other intellectual property rights and industrial property rights, subject matter of any of the foregoing,

tangible embodiments of any of the foregoing, rights under licenses in, to and under any of the foregoing, and the right to make applications

for any of the foregoing, extensions and renewals thereof, and all rights of a similar nature, in each case anywhere in the world.

“IRS”

means the U.S. Internal Revenue Service.

“Law”

means any federal, state, local or foreign law (statutory, common, or otherwise), constitution, treaty, convention, ordinance, equitable

principle, code, rule, regulation, consent decree, order, decree, judgment, settlement agreement, request, governmental requirement or

other similar requirement enacted, adopted, promulgated, entered into, agreed, imposed or applied by any Governmental Authority, each

as amended and now and hereinafter in effect.

“Loss”

means, with respect to an Indemnified Party, any and all losses, liabilities, damages, deficiencies, penalties, fines, costs, and expenses

(including reasonable attorneys’ fees and costs of investigation) paid or incurred by such Indemnified Party in respect of a claim

for indemnification pursuant to Article. For clarity, “Losses” shall not include punitive damages except to the extent

actually awarded to a third-party, but shall include consequential, special, and indirect damages that are reasonably foreseeable.

“Order”

means any order, writ, ruling, decision, decree, consent decree, judgment, award, injunction, settlement, stipulation or other determination

in each case, issued, promulgated, made, rendered, or entered into by, or with, any Governmental Authority, whether temporary, preliminary

or permanent.

“Person”

means an individual, partnership, corporation, business trust, limited liability company, limited liability partnership, joint stock

company, trust, unincorporated association, joint venture or other entity or Governmental Authority.

Collaboration Agreement Page 8 of 9

“Representative”

means, with respect to a Person, its Affiliates and its and their respective managers, officers, employees, consultants, counsel, accountants,

and other agents, as the case may be.

“Transaction

Document” means collectively, this Agreement and all other agreements, certificates, documents, or other instruments to be

executed and delivered by any Party in connection with the Contemplated Transactions, including without limitation any disclosure schedules,

exhibits, and ancillary agreements.

“Pre-Closing

Tax Period” means any taxable period ending on or before the Closing Date and, with respect to any taxable period beginning

before and ending after the Closing Date, the portion of such taxable period ending on and including the Closing Date.

WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed as of the day and year first above written.

WELLGISTICS HEALTH, INC.

KARE RX HUB, LLC

By:

/s/ Prashant Patel

By:

/s/ Mital Panara

Name:

Prashant Patel

Name:

Mital Panara

Title:

President

Title:

Manager

HEALTHSTAR TECHNOLOGIES

KARE PHARMTECH, LLC

By:

/s/ Prashant Patel

By:

/s/ Mital Panara

Name:

Prashant Patel

Name:

Mital Panara

Title:

President

Title:

Manager

Collaboration Agreement Page 9 of 9

EX-99.1

Filename: ex99-1.htm · Sequence: 3

Exhibit

99.1

Wellgistics

Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives

●

Joint venture

executed combining Wellgistics Hub and KareRx Hub technology and operations

●

Integrated platform

accelerates pharmaceutical access, fulfillment, and commercialization

●

Combined ecosystem provides

potential reach to an estimated 200,000+ patient lives across pharmaceutical and provider networks

TAMPA,

FL / ACCESS Newswire / April 14, 2026 / Wellgistics Health, Inc. (NASDAQ:WGRX) (“Wellgistics” or the “Company”),

a leading healthcare technology and pharmaceutical distribution

company, today announced the execution of a definitive joint venture agreement with Kare PharmTech’s wholly owned subsidiary, Kare

Rx Hub, LLC (“KareRx”), an artificial intelligence (AI)-driven digital hub supporting retail pharmacy, telemedicine, and

specialty pharmaceutical programs.

The

execution of the joint venture formalizes the previously announced non-binding letter of intent and represents a significant milestone

in aligning both organizations’ technology platforms and operational teams into a unified ecosystem designed to accelerate patient

access and improve the efficiency of pharmaceutical commercialization. By integrating the Wellgistics Hub technology stack including

proprietary platforms EinsteinRx™ and HubRx AI™ with KareRx’s digital hub, the combined platform is positioned to streamline

the prescription journey from intake through fulfillment.

Prashant

Patel, Chief Executive Officer of Wellgistics Health, commented, “This joint venture reflects our continued focus on building an

integrated, technology-enabled platform to improve coordination across the prescription journey and support patient access to therapies.

By combining KareRx’s provider connectivity and digital engagement capabilities with our infrastructure, we believe this collaboration

enhances operational efficiency and supports manufacturers and other healthcare stakeholders in navigating access pathways more effectively.”

The

joint venture aligns clinical, operational, and commercial teams across both organizations, enabling more seamless coordination between

providers, pharmacies, and patients. Through this integration, the platform enhances key capabilities including eligibility and benefits

verification, prior authorization workflows, prescription routing, and direct-to-patient fulfillment. The combined ecosystem includes

a growing national footprint of independent pharmacies, provider networks, and telehealth channels, with the ability to reach more than

200,000 patient lives based on third-party internal estimates.

Mital

Panera, Founder and Chief Executive Officer of KareRx, added, “KareRx was developed to connect providers, pharmacies, and patients

through technology-driven solutions. This joint venture allows us to extend those capabilities by leveraging Wellgistics’ technology

stack, pharma expertise, and operational infrastructure. We believe the combined platform will support improved connectivity across stakeholders

and facilitate access to therapies across participating networks.”

The

collaboration further strengthens direct-to-patient (DTP) and decentralized care models, providing pharmaceutical manufacturers with

a comprehensive platform that integrates access, affordability, and fulfillment into a single solution. Leveraging AI-driven insights

and a fully integrated operational backbone, the joint venture is designed to reduce barriers to therapy initiation, improve adherence,

and deliver enhanced visibility into patient access and program performance.

The

joint venture remains subject to customary implementation steps, and there can be no assurance regarding the timing or extent of operational

integration or the realization of anticipated benefits. Additional details regarding the joint venture agreement will be provided in

a Current Report on Form 8-K to be filed by the Company with the U.S. Securities and Exchange Commission.

About

Wellgistics Health, Inc.

Wellgistics

Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence

platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription

drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the “Wellgistics Pharmacy Network”) and 200+

manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services

such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics

provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent

pharmacies.

About

Kare PharmTech, LLC

Kare

Rx Hub is an artificial intelligence (AI)-based digital hub for retail pharmacies, telemedicine portal, and specialty pharmaceutical

‘lite’ branded products with over 500 physician-provider relationships, 200 independent pharmacy relationships that market

unique specialty pharmaceutical ‘lite’ products. Kare Rx Hub is owned by Kare Pharmtech, LLC, a company controlled by Dr.

Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America’s

1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America’s 1st Choice Holdings to Anthem,

Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.

Forward-Looking

Statements

This

press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals,

strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical

facts. When Wellgistics Health uses words such as “may,” “will,” “intend,” “should,”

“believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions

that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without

limitation, statements regarding Wellgistics Health’s strategy and descriptions of its future operations, prospects, and plans.

Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results

to differ materially. Additional factors are discussed in Wellgistics Health’s filings with the SEC, available at www.sec.gov.

GRAPHIC

Filename: ex99-1_001.jpg · Sequence: 4

Binary file (30469 bytes)

Download ex99-1_001.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 20

v3.26.1

Cover

Apr. 17, 2026

Cover [Abstract]

Document Type

8-K/A

Amendment Flag

true

Amendment Description

This

Amendment No. 1 to the Current Report on Form 8-K filed on April 17, 2026 is being filed to include disclosure required under Item 3.01

that was inadvertently omitted.

Document Period End Date

Apr. 17, 2026

Entity File Number

001-42530

Entity Registrant Name

WELLGISTICS

HEALTH, INC.

Entity Central Index Key

0002030763

Entity Tax Identification Number

93-3264234

Entity Incorporation, State or Country Code

Entity Address, Address Line One

3000

Bayport Drive

Entity Address, Address Line Two

Suite

950

Entity Address, City or Town

Tampa

Entity Address, State or Province

Entity Address, Postal Zip Code

33607

City Area Code

(844)

Local Phone Number

203-6092

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.0001 par

value per share

Trading Symbol

WGRX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Description of changes contained within amended document.

+ References

No definition available.

+ Details

Name:

dei_AmendmentDescription

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration